What 8 Analyst Ratings Have To Say About Genmab
What 8 Analyst Ratings Have To Say About Genmab
关于genmab，8位分析师的评级是怎样的？
During the last three months, 8 analysts shared their evaluations of Genmab (NASDAQ:GMAB), revealing diverse outlooks from bullish to bearish.
在过去的三个月中，8位分析师分享了他们对Genmab（纳斯达克股票代码：GMAB）的评估，揭示了从看涨到看跌的不同前景。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
下表总结了他们最近的评估，说明了过去30天不断变化的情绪，并将其与前几个月进行了比较。
Analysts have set 12-month price targets for Genmab, revealing an average target of $50.0, a high estimate of $53.00, and a low estimate of $47.00. This upward trend is apparent, with the current average reflecting a 1.01% increase from the previous average price target of $49.50.
分析师已经为Genmab设定了12个月的目标股价，显示平均目标股价为50.0美元，最高估计为53.00美元，低估值为47.00美元。这种上升趋势显而易见，当前的平均价格较之前的平均目标价49.50美元上涨了1.01％。
Diving into Analyst Ratings: An In-Depth Exploration
深入分析师评级：深度探索
A clear picture of Genmab's perception among financial...
通过对分析师近期行...
登录免费看全文
登录/注册